Vasily A. Shuvaev
Saint Petersburg, SPE, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Journal: JAMA oncology
Published: November 21, 2024
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2023
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Journal: Frontiers in oncology
Published: January 23, 2023
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Journal: Annals of internal medicine
Published: February 21, 2018
Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy
Journal: Terapevticheskii arkhiv
Published: February 08, 2018
The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.
Journal: British journal of haematology
Published: June 14, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026